Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

被引：0
作者：
T J Price
M A Bruhn
C K Lee
J E Hardingham
A R Townsend
K P Mann
J Simes
A Weickhardt
J W Wrin
K Wilson
V Gebski
G Van Hazel
B Robinson
D Cunningham
N C Tebbutt
机构：
[1] The Queen Elizabeth Hospital,Haematology
[2] School of Medicine,Oncology Department
[3] University of Adelaide,undefined
[4] School of Medical Sciences,undefined
[5] University of Adelaide,undefined
[6] NHMRC Clinical Trials Centre,undefined
[7] The University of Sydney,undefined
[8] Austin Health,undefined
[9] Ludwig Institute for Cancer Research,undefined
[10] Sir Charles Gardiner Hospital,undefined
[11] Christchurch Hospital,undefined
[12] Royal Marsden Hospital,undefined
来源：
British Journal of Cancer | 2015年 / 112卷
关键词：
VEGF; bevacizumab; colorectal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：963 / 970
页数：7
相关论文
共 3 条
  • [1] Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
    Price, T. J.
    Bruhn, M. A.
    Lee, C. K.
    Hardingham, J. E.
    Townsend, A. R.
    Mann, K. P.
    Simes, J.
    Weickhardt, A.
    Wrin, J. W.
    Wilson, K.
    Gebski, V.
    Van Hazel, G.
    Robinson, B.
    Cunningham, D.
    Tebbutt, N. C.
    BRITISH JOURNAL OF CANCER, 2015, 112 (06) : 963 - 970
  • [2] The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study
    Carter, Hannah E.
    Zannino, Diana
    Simes, R. John
    Schofield, Deborah J.
    Howard, Kirsten
    Zalcberg, John R.
    Price, Timothy J.
    Tebbutt, Niall C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (03) : 535 - 543
  • [3] Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study
    Nagasaka, Takeshi
    Mishima, Hideyuki
    Sawaki, Akira
    Shimokawa, Mototsugu
    Inukai, Michio
    Shinozaki, Katsunori
    Tanioka, Hiroaki
    Nasu, Junichiro
    Nishina, Tomohiro
    Hazama, Shoichi
    Okajima, Masazumi
    Yamaguchi, Yoshiyuki
    BMJ OPEN, 2016, 6 (06):
1